Mind Medicine (MindMed) Inc. (DFTX) Earnings Call Transcript
November 6, 2025
Earnings Call Speaker Segments
Thanks, operator, and good afternoon to all of you. We appreciate you being here today as we go over MindMed's Third Quarter 2025 Business Highlights and Financial Results. Rob Barrow, our Chief Executive Officer, will be the one guiding today's call. Also joining us on the line are Dr. Dan Karlin, our Chief Medical Officer, and Brandi Roberts, our Chief Financial Officer. A replay of the audio recording and webcast for this conference call will be accessible online, with details provided in the press release announcement for today's call. During this call, we'll be making some forward-looking statements. These cover things like how safe and effective our product candidates might be, how far they could get in regulatory and clinical terms, how long our cash will last, and what we expect, plan, and hope for regarding partnerships and prospects. Such statements come with a range of risks — for instance, shifts in market conditions, plus challenges related to research and development and the regulatory approval process. You can find these and other risk factors in what we've filed with the SEC and the relevant Canadian securities regulators, which includes our Form 10-K annual report and the Form 10-Q we filed today. Statements about the future depend on what management assumes, believes, and estimates as of the date they're issued — this includes the idea that the risks and uncertainties outlined in documents filed with the SEC and relevant Canadian securities regulators won't materialize, and that no other major events will take place beyond MindMed's ordinary business activities. A word of warning: don't lean too heavily on these forward-looking statements, since they reflect conditions only as of today, November 6, 2025. Even if management's perspective shifts, MindMed has no duty to revise these statements, unless the law demands it. On that note, I'll hand things over to Rob.
Thanks, Gita, and thanks to all of you for being on the call today. We turned in yet another strong quarter, moving our clinical programs forward and continuing to build out one of the deepest late-stage pipelines in our sector; on top of that, during this quarter our complete Phase IIb clinical trial results appeared in the Journal of the American Medical Association, underscoring how rigorous and impactful the clinical data we've produced so far have been. Riding that scientific momentum, last week we closed an underwritten public offering, bringing in roughly $259 million in gross proceeds. With this added capital, our balance sheet is even stronger, and we can deliberately speed up development of MM120 and MM402. Our shareholder mix continues to expand and strengthen—we've attracted additional top-tier funds focused on health care as well as mutual funds, and at the same time existing investors have stepped up their commitment. This financing speaks to the quality of our science and positions us for a 2026 that will transform the company. It's a decisive year, with 3 Phase III readouts on the top line anticipated in our generalized anxiety disorder, or GAD, and major depressive disorder, or MDD, programs. Enrollment remains robust and consistent throughout the pivotal MM120 trials we have underway. Our guidance is unchanged: we continue to anticipate top line data from Voyage during the first half of 2026, and from Panorama during the second half of 2026. Because people signed up for the trial faster than we had expected over the last quarter, we now anticipate topline data from the Emerge study around the middle of 2026 — a change from what we previously told you, which was the latter half of 2026. On top of that, we look forward to providing additional information on Ascend, the second Phase III trial of MM120 for MDD, which should kick off around mid-2026. Our approach remains to direct funding and get our programs up and running as efficiently as possible while we work toward approvals in GAD and MDD, two of the psychiatric conditions that affect the most people and cause the greatest burden. All through 2025, we have kept up productive talks with FDA, and we feel we are in a strong position to achieve a swift route ahead across both indications. For a very long time now, people dealing with anxiety and depression simply haven't gotten enough help from the treatments available today. A lot of them go through one therapy after another and see only modest improvements. What they want is a different path — a new option that's both safe and effective, one they can trust to bring real, meaningful change rather than merely holding symptoms down. Given the safety profile, the efficacy, and the durability we've shown so far with MM120 ODT, we think this could be exactly that kind of transformative choice, treating anxiety and depression via a delivery model that's efficient and centered on the patient. And it's worth keeping in mind that everything we've observed in our results up to this point came from one single dose given as a monotherapy, with no psychotherapy provided alongside it. Our view is that MM120 ODT has the potential to fit smoothly within today's health care system, drawing on widely accepted reimbursement codes that address assessment, prescription and oversight, along with the therapy itself. Our goal is to reduce the barriers that hinder adoption and to ensure that doctors are fairly compensated for the hours and effort they devote. Now, regarding the rest of our R&D work, we're pleased to share an important update on MM402, the second candidate in our pipeline, which is MDMA's R-enantiomer. A single ascending dose Phase I trial of MM402 in healthy adult volunteers has already been finished, and we intend to launch a Phase IIa trial in people who have autism spectrum disorder, or ASD, before 2025 comes to a close. In our view, ASD is yet another major opportunity, given rising prevalence and considerable unmet need. As we head into the final months of 2025, everyone on our team stays sharply focused on carrying out the studies now underway and preparing the ground for a transformational 2026 and beyond. Looking ahead, we anticipate three key data readouts for MM120 ODT in GAD and MDD during 2026, along with the launch of our second pivotal MDD trial that same year. MM402 for ASD should enter a Phase II study by the close of 2025, and we'll keep advancing our go-to-market strategy as we prepare for a potential MM120 ODT launch. Momentum is strong across all areas, and we're working hard to bring transformative treatment options to the many patients in need of new choices. With that, I'll pass things over to Dan for an update on our clinical programs.
Thanks, Rob. The enrollment patterns across our pivotal Phase III trials keep giving us a lot of encouragement. As Rob said before, for GAD, our expectation is to share Voyage data during the first half of 2026 and Panorama data during the second half of 2026. Because enrollment has been particularly strong in Emerge, our ongoing MDD trial, we're thrilled that we can now report Emerge results in mid-2026. Also during this quarter, the complete results of our Phase IIb trial were published in the Journal of the American Medical Association, or JAMA. That's a major milestone, not only for our company but for psychiatry as a whole. This trial is the most rigorous randomized, placebo-controlled study of Lysergic D-tartrate, or LSD, ever run in a psychiatric population using contemporary scientific standards. A single treatment was assessed at 4 dose levels — 25, 50, 100 and 200 micrograms — and it showed compelling clinical activity, with a dose response that was statistically significant. At our optimal 100-microgram dose, the effects were both rapid and durable, with a statistically significant 7.7-point greater reduction in HAM-A compared with placebo at week 12. On top of that, 65% of patients in the 100-microgram cohort demonstrated clinical response, and 48% reached remission 12 weeks after receiving a single dose of MM120. Now turning to our Phase III program. Each of our GAD trials contains 2 parts: Part A, a 12-week randomized, double-blind, placebo-controlled evaluation of MM120 ODT against placebo; and Part B, a 40-week extension phase offering open-label treatment opportunities, which lets us assess long-term durability and response patterns. For Voyage, our enrollment target is roughly 200 participants, who are randomized 1:1 to MM120 ODT 100 micrograms or placebo. For Panorama, our enrollment target is 250 participants, who are randomized 2:1:2 to MM120 ODT 100 micrograms, 50 micrograms or placebo. These Phase III trials are modeled on our successful Phase IIb study, with the Hamilton Anxiety Scale, or HAM-A, serving as the primary outcome measure — the same measure used when existing GAD therapies were approved. The primary endpoint for our Phase III trials is the HAM-A change from baseline to week 12. Building on what our Phase IIb results achieved, even though we saw a 7.7 point placebo-adjusted improvement in Phase IIb, we designed our Phase III trials with 90% power to detect a 5-point improvement over placebo. We also designed our Phase III trials to address functional unblinding, something that frequently comes up when people discuss the research methods used to investigate drugs in the broader psychedelic category. Obviously, MM120 ODT and other drugs in this category produce a distinctive set of perceptual, cognitive and emotional effects at the time they are administered. Though the phenomenological character of these effects is unique to the category, the vast majority of approved psychiatric drugs likewise have acute effects that lead to participant unblinding. That said, to get the most integrity, reliability, interpretability, and generalizability out of our research, we've put in place a group of interventions meant to tackle this and other methodological issues throughout our Phase IIb and Phase III programs. Those include relying on central raters who don't know either the treatment assignment or the visit number, adding questionnaires to measure possible expectancy bias and unblinding, and, in several of our trials, adding extra control arms that participants can substantially tell apart but that aren't relevant when we assess clinical efficacy. Our ongoing talks with FDA also back up how well-aligned and rigorous our approach is, strengthening our confidence that our development strategy can produce definitive, clear, and compelling proof of the safety and efficacy of MM120 ODT in GAD and MDD. Shifting to our MDD program. We're taking a similar tack as with our GAD program, which involves 2 pivotal studies that use the same 2-part structure. Both of our pivotal MDD trials, Emerge and Ascend, have 2 parts: Part A, a 12-week randomized, double-blind, placebo-controlled parallel group period that assesses efficacy and safety of a single dose of MM120 ODT versus placebo; and Part B, a 40-week extension period with chances for open-label treatment. The primary endpoint for each study is change from baseline on the Montgomery-Asberg Depression Rating Scale, or MADRS, at week 6 between MM120 ODT 100 micrograms and placebo. For Emerge, we're aiming to enroll at least 140 participants randomized 1:1 to MM120 ODT 100 micrograms or placebo. We now expect top line data from Emerge in mid-2026. In Ascend, our second pivotal MDD study, we're targeting enrollment of at least 175 participants randomized 2:1:2 to receive MM120, 100 micrograms, 50 micrograms or placebo. We expect to start Ascend in mid-2026. On to our next pipeline candidate. We're excited to reveal our plans to move MM402, the R-enantiomer of MDMA, forward. In preclinical studies, MM402 has demonstrated promising prosocial effects along with a potentially better tolerability profile than both racemic MDMA and the S-enantiomer of MDMA. We're developing MM402 to go after the core symptoms of autism spectrum disorder, specifically tackling social communication challenges. We think this program offers another major treatment opportunity given the high unmet need, the rising prevalence of ASD, and the absence of FDA-approved therapies that specifically target these core symptoms. After finishing a Phase I single-ascending dose study that characterized the tolerability, pharmacokinetics and pharmacodynamics of MM402 in healthy adult volunteers, we plan to launch a Phase IIa study later this year. That study will use a single-dose open-label design, assessing early signals of efficacy in up to 20 adult participants with ASD. The study's objectives and endpoints are built to characterize the pharmacodynamics and clinical effects of MM402 in adults with ASD across multiple functional domains; in short, we're executing efficiently across our pipeline. The Phase III efforts we consider central for MM120 ODT, covering GAD as well as MDD, are still moving forward as expected, with results due to be reported in the coming year. In addition, we intend to launch Ascend, which is our second Phase III trial in MDD, around the middle of 2026. While we keep pushing MM120 ODT toward the market, we're equally enthusiastic about moving our MM402 program for ASD ahead, which continues our pursuit of pioneering therapies for patients whose needs are not yet met. So with that, I'll hand things over to Brandi so she can walk us through the financial results for our third quarter. Brandi?
Appreciate that, Dan. Now for our financials covering the quarter that closed on September 30, 2025 — we finished that period holding cash, cash equivalents and investments of $209.1 million altogether. Rob mentioned this earlier, and indeed we closed an underwritten public offering successfully just last week, generating $258.9 million in gross proceeds. Once underwriter commissions and expenses are subtracted, the net proceeds come to $242.8 million. The result of this recent financing has us quite pleased, and it places us in a terrific spot going forward. The strong interest from high-quality investors in MindMed and in our development programs was encouraging to see, and it clearly reflects how much confidence the investment community holds in our mission. With this funding, we can speed up key initiatives designed to set MM120 up for success, such as NDA preparation, state prioritization efforts for scheduling, market research and KOL education, among others. These efforts put us in a good position to act quickly in the years ahead — pursuing submission of an NDA for MM120 ODT as soon as possible and, should approval come, carrying out a robust and well-prepared commercial launch. Given the company's current operating plan and anticipated R&D milestones, the company believes its cash, cash equivalents and investments as of September 30, 2025, together with the net proceeds from their recent offering, will be enough to fund the company's operations into 2028. Third quarter 2025 expenses matched our internal expectations, as we keep making significant progress with MM120 and MM402. R&D expenses came to $31 million for the third quarter of 2025, versus $17.2 million for the third quarter of 2024 — a rise of $13.8 million. That overall increase stemmed mainly from increases of $11.7 million in MM120 program expenses, $2.5 million in internal personnel costs, reflecting expanded research and development capabilities, and $200,000 in preclinical and other program expenses; a $600,000 reduction in MM402 program expenses partially offset these amounts. G&A expenses were $14.7 million for the third quarter of 2025, versus $7.6 million for the third quarter of 2024 — an increase of $7.1 million. That increase stemmed mainly from increases of $3 million in personnel-related expenses, $2 million in commercial preparedness related expenses, $1.6 million in corporate affairs expenses and $500,000 in other miscellaneous administrative expenses. Net loss for the third quarter of 2025 came to $67.3 million, versus $13.7 million for the same period in 2024. Keep in mind that changes in the fair value of our 2022 USD financing warrants can dramatically impact our net loss from quarter-to-quarter as our stock price fluctuates. The change in fair value for the third quarter was $22.5 million, as our stock price rose from $6.49 at June 30, 2025, to $11.79 at September 30, 2025. I'll also note that warrant exercises related to the 2022 financing have brought in approximately $2.5 million of cash this year, with an additional $17.6 million of potential funding remaining prior to the warrant expirations in 2027. Having said that, I'll hand things back to Rob at this point so he can wrap us up.
Thanks, Brandi. Bold ambition and disciplined execution have really defined the past year for us. Our programs are being delivered, and we're actively helping to shape what we think the future can be. Across all 3 of our ongoing pivotal trials — Voyage, Panorama and Emerge — enrollment is still strong, and we're eager to keep that momentum going when our second pivotal MDD trial, Ascend, kicks off in mid-2026. Alongside that, MM402 is moving into a Phase II study, which is a meaningful milestone as we try to bring much needed innovation to the ASD community. It looks like 2026 will be a defining year in our evolution, a year in which science, purpose and precision come together to push forward the therapeutic potential of MM120 across our broader pipeline; with a strong balance sheet and a late-stage pipeline that has multiple catalysts in the year ahead, we're excited to keep driving value for our shareholders and for the millions of patients who deserve more than better. Naturally, none of this progress happens without our exceptional team, whose passion, commitment and unmatched execution keep setting the standard for our field. Thanks again for joining our call today; we'll now open the line for questions.
Yesha here, filling in for Gavin. We touched on the blinded sample size re-estimation quickly before. Mainly, I'm curious whether that's now finished. And if it is, since the expected trial size remains 200 patients, does it make sense to conclude the trial isn't being upsized?
Thanks a lot, Yesha. Right, we haven't said anything regarding a public disclosure of our sample size re-estimation. And I'm not sure if you mean the ability to boost the sample size so as to keep 90% power in both Voyage and Panorama, our 2 GAD studies. So, enrollment continues to excite us, and we remain on track for a readout in that program next year, but we've still not said anything publicly about those announcements.
Sarah Medeiros here, standing in for Pete. Nice work on the quarter's advances. I have 2 questions, really. First, I'm wondering how simple or hard it is to locate patients ready to sign up for the psychedelic — people ready to sign up who haven't tried psychedelics before and are naive, given all the scrutiny on this drug class for psychiatric uses. Also, is there a particular demographic, like patient age, that's ready to sign up?
Yeah. Sarah, I really appreciate that question. I'll hand it to Dan, who can perhaps fill in.
Yeah. So, look — I'd never claim that getting a trial enrolled is simple, since that's clearly something we work at every single day and spend time figuring out how to bring the right patients into our studies. What we've kept up, and what we aim toward, is a sample that's representative, so that we observe a background epidemiological rate of individuals with some psychedelic experience sitting at roughly 15%; and that's generally the target we set for our research. Our goal is a sample resembling the overall GAD population. That's what we ultimately had in our Phase IIb study, and that's what we're working toward in our Phase III study, in which we are, to a meaningful degree, applying the same inclusion/exclusion criteria; so, even though there's attention on these studies and attention on the category, naturally, for those of us inside it, that attention stands out far more. A lot of the participants who come across our studies are simply individuals seeking studies for their GAD or MDD. And the vast majority don't locate the studies because they're specifically searching for a study within the psychedelic category or even, necessarily, for our study.
Thanks, and one more thing on that: could you walk us through the science and the treatment case for MM402, your earlier-stage program, along with the ASP, the kind of results you'd expect, and a possible trial design when it comes to giving it chronically? Also, is at-home dosing something you're considering?
That's a great question. Clearly, much of the recent focus on the company has centered on our lead asset, and naturally we're very excited about MM402. What's interesting about the way we envision deploying R-MDMA, or MM402, is that within our development strategy we're building it as a medication taken either every day or on an as-needed basis; the closest comparison class, then, would be psychostimulants for ADHD, where individuals with attentional problems can take psychostimulants to boost their capacity to focus while in settings or engaged in tasks where that would help. So, based on whatever discussion a person has with their physician, that could be at school, at family gatherings, or anything else the care provider and the patient jointly judge suitable; we definitely envision 402 operating along those lines. The particular acute and transient effects of 402, or R-MDMA, are of course greater social awareness and social communication. Individuals grow more tuned in to their own feelings, and possibly those of other people; and naturally, a central difficulty for those with ASD is, and can be, trouble with those kinds of social communication scenarios and with recognizing emotions in themselves and in others. So we believe the drug's quite direct impact, while it's active, is precisely what will help people facing those challenges. As we've now made public, we're heading toward an early efficacy signal study in which we'll seek signs that the drug is doing what we expect, grounded in the preclinical data and some academic clinical evidence; and clearly, that will shape our continued development of the drug.
This is Nevin, filling in for Brian. Nice work on a solid quarter thus far, plus all the recent announcements. I just wanted to ask about some of the implications, or possible implications, I suppose, that we noticed from another company in this space that had just given an update on a faster schedule too, for one of its trials. Could there be some fundamental explanation why, in this instance, the Emerge study was sped up, while the GAV studies weren't, and I believe with that competitor, it was a depression trial. So, might that be tied to the specific indication being examined? Or is it more related to the enthusiasm surrounding psychedelics? And after that, could you offer any further clarity or detail regarding when Voyage and Panorama will report out? I suppose, how does the enrollment speed in those pivotal trials compare with what was observed in the Phase IIb?
Yes. Thank you very much for asking, Nevin. Yes, clearly, we can't comment on other businesses and their activities in their trials, but we've felt very encouraged overall and enrollment has been robust in all 3 of our active studies; and, once more, we remain quite encouraged and dedicated to meeting our timelines with readouts coming next year; regarding Emerge, we definitely began that study pretty early in relation to the timeframe we had originally communicated, and we keep seeing strong enrollment overall. We certainly don't think there's any meaningful distinction between GAD and MDD, and we keep witnessing considerable involvement, throughput, and randomizations throughout all 3 studies. So, we're on schedule and eager about obtaining 2 topline readouts as steered next year.
If I could also pose one more question; since the Emerge study appears as though it will produce results roughly 12 months or so after beginning, might we expect a comparable duration for the Ascend trial, possibly somewhat longer simply because of the larger enrollment? Then, on a wider note, considering the latest — considering the recent capital raise and the solid cash balance, why not simply kick off the MDD studies or the Phase III Ascend study at an earlier point? What is the reason, I suppose, for holding off — or what justifies delaying until the initial one reports?
Yes. Thank you. Thanks to the recent financing, and we consider ourselves extremely lucky for the backing we've gotten and the way it places us as we head into next year, and we're speeding up on all fronts. Thus, we definitely are not idly standing by and waiting on anything. We prefer to establish schedules where we're confident we can achieve them, and that genuinely shaped how we approached the schedules that have been made public. Yet naturally, whenever we get a chance to speed those schedules up and move study starts and move data readouts sooner than expected, we will absolutely seize those chances. So, everything is full steam ahead in both programs and all our efforts.
Congratulations on everything you've accomplished. And nice work on getting into JAMA. I'd like to know what kind of response you've gotten from physicians regarding that piece up to now. More broadly, what does publishing there signify for those working in psychiatry? Also, from the data itself, is there anything that comes up in your conversations which you feel people still don't fully recognize? Then I have a single additional question.
Sure, Dan will take that one.
Yeah. Every aspect of how we designed, executed, and eventually reported that trial was intended to be an easily understood, conventional study design and analysis plan that physicians and other people in this field could read and completely grasp. We've put genuine effort into making sure our claims were strongly backed by the data we could produce, and clearly, the findings we could reach from that trial have enabled us to advance with breakthrough designation and into a Phase III program that in many — essentially all design respects, apart from the number of arms, is almost the same as the successful Phase II. So I believe that's acknowledged and valued across the physician community and among all the other stakeholders we deal with. So the response has been extremely favorable. And we take pride in what we accomplished, and we're very happy about what it signals regarding what we expect to be able to demonstrate in the Phase III programs. I think regarding what may be underappreciated, perhaps it's the idea of a single monotherapy treatment with no kind of adjunctive therapy being capable of producing remission in slightly less than 50% of the patient population who begin with, on average, severe GAD and then at 12 weeks seeing that level of remission from one intervention. I think even — regardless of how often we examine these data, and we probably examine them more than anyone, it still seems to me to be genuinely, genuinely a remarkable opportunity for a potential sea change in psychiatry.
Then there was one more thing we wanted to ask, if that's alright: could you discuss, purely from a commercial standpoint, how you intend to handle patients in practice given that administration takes 8 hours in the clinic? We hear a lot of questions about the difficulties people perceive, which you might be able to address in real-world use. And perhaps you could frame that against SPRAVATO by discussing the total treatment time across a year — that would be much appreciated.
Yes. Thank you very much. When Spravato comes up, clearly it has drawn considerable focus, and that's genuinely encouraging. What encourages me most is that psychiatry does adapt, and will adapt, as new treatment options arrive. Yet the way responses behave — both their dynamics and how long they last following a Spravato session — stand in sharp contrast to the long-lasting, durable effects MM120 has demonstrated thus far. So yes, certain parallels exist. From an infrastructure and delivery perspective, some dynamics have been sorted out since Spravato launched, and we absolutely think we can take advantage of that. Still, comparing the two is nearly like comparing apples to oranges once we consider the treatment dynamics and the benefits our clinical trials have shown to date. That speaks to the enormous demand for MM120 we hear from patients and providers alike whenever we conduct research with those groups. And again, to be clear, MM120 is not, and never was, meant to replicate Spravato. In our view it brings meaningful advantages, both in how large the change is and in how long that change persists — which leaves it positioned extremely well. So once more: excellent learnings, excellent infrastructure we can build on, but an entirely different dynamic — one we consider quite favorable next to any drugs currently on the market for these indications.
So, the initial thing I wanted to ask about was the market potential in this case, comparing MDD with GAD. Could you just say a bit regarding how they overlap? And clearly, these are enormous, enormous markets, but is it possible for one to cannibalize the other? Or perhaps just a clearer grasp of what distinguishes the two?
Yeah. I'll hand it over to Dan as well to discuss it from a clinical standpoint shortly. I suppose in terms of market opportunity, there definitely is a lengthy track record of medications receiving labels for MDD, GAD, and additional psychiatric indications. A number of the largest psychiatric drugs over time have carried labels for both of these indications. And usually, those medications — and here I'm referring to SRIs — began with an MDD label and later broadened into GAD, and we believe that reflects the difficulties and the shortcomings of such medications when it comes to addressing GAD symptoms. So, although there is definitely a substantial degree of overlap, we don't view it as — not so much about cannibalizing anything as it is about providing a chance to basically address 2 core symptom clusters that intersect within the diagnosis. But in a best-case scenario, any patient who comes in with anxiety or depression symptoms and meets the criteria for diagnosis could then be guided toward MM120, assuming we succeed in securing both indications on the label. But I'll hand it over to Dan, who might say a bit more regarding the clinical presentation.
Yes, and I appreciate that question, Frank. The way these 2 conditions intersect is genuinely fascinating. What we've arrived at is this: certainly, some patients experience a major depressive episode, get a major depressive disorder diagnosis, yet between those episodes they don't carry GAD-level anxiety — so when euthymic, depression isn't present. Meanwhile, others have GAD with persistent, non-episodic, elevated anxiety, and they never develop a major depressive episode. For 50% to 80% of individuals receiving either diagnosis, both would apply. That means these are people whose background anxiety has generally been quite high, frequently across most of their lives. Since they don't realize you aren't meant to feel that way — and until recently, no screening recommendation existed for anxiety disorders — well, that shifted in the last 3 years when USPSTF issued anxiety screening recommendations. It's almost like, this is simply how you're supposed to feel, and many intellectualize it by reasoning, well, the world is frightening and unsafe, so naturally I'm anxious constantly. A large share of those individuals eventually experience a major depressed episode, and given how episodic the condition is, they wind up pursuing care in an environment with greater depression screening — that recommendation has existed far longer — plus the condition shifts overnight. So people may then pursue care when a major depressive episode begins. Thus, as Rob put it, you treat one symptom set within the symptom cluster — the anxiety component or the more anhedonic depression component — rather than fretting about cannibalizing a market; the point is delivering people overall relief from their distress, unlike drugs that merely demonstrated efficacy at ending a major depressive episode while leaving patients in that euthymic yet highly anxious state between depressive episodes. So we're truly enthusiastic that we could demonstrate the efficacy we did in Phase II for GAD, along with the remarkable effect shown in those patients on MADRS scores. We're therefore highly optimistic regarding our Phase III program in MDD too. And once more, we view this as additive benefit for people who, in most cases, are essentially suffering from both.
Excellent, that's a big help. Then perhaps only one item remains: regarding the KOL education mentioned as a future item to address — for an area that has lacked many fresh choices for quite some time, what do you see as the largest obstacles involving KOLs? Is it straightforward, with the data essentially making the case on its own? Or do you anticipate that among the various tiers of KOLs, certain individuals will be far more open to trying a novel approach, perhaps sooner within the treatment paradigm? I'm simply curious where you believe the greatest difficulties lie for the KOL education effort.
Right. Since I've been present globally at the conferences and collaborating with numerous such KOLs across the past several years, we feel tremendously heartened by the powerful appetite for a new option, and heartened by the — I believe the esteem that rigorous evidence has earned from KOLs and from practicing psychiatrists at essentially every tier. Thus, we can't — it's nearly impossible to exaggerate how eager so many of those discussions turn out to be. Of course, there are certainly critics. A considerably smaller group exists, yet there will be a portion of practicing psychiatrists who probably have no interest in administering MM120. However, what we observe is that an overwhelming majority in our discussions with KOLs, and once more, practicing psychiatrists in the field who — a lot of them state, well, I'm not equipped and wouldn't provide any interventional psychiatry treatments at present, yet I definitely intend to do so with MM120, assuming it receives approval; therefore, although a significant undertaking lies before us so that we may shape the market and ensure the world completely understands the thrilling data we are producing, we perceive no kind of obstacle when it comes to securing that type of engagement. Moreover, if anything, it's rather uncommon to witness the level of excitement that we do as a field this early and ahead of pivotal readouts, and this stretches back several years now. So, I stay extremely encouraged yet extremely concentrated on getting that messaging correct and spreading it as widely as we can.
Also, is Spravato a factor in this? Or would you say the two are so distinct that a person prescribing Spravato wouldn't necessarily be any more inclined to prescribe this one?
Honestly, whatever infrastructure has been built out, we see that as something we're able to take advantage of, and for providers — frankly, when providers have been running as many SPRAVATO treatment sessions as they've done across the last several years, and then they encounter a therapy with greater magnitude and a more lasting effect that appears to produce an entirely different type of result for certain of these patients, that comparison makes us feel quite confident and we believe it puts us in a very strong position. So yes, we do think a portion of psychiatry is providing not just Spravato but also other interventional psychiatric therapies. Those providers tend to rank among the earlier adopters and among the most eager, though it's definitely not confined to Spravato centers or to providers who approach us to share their excitement about what MM120 might deliver for patients.
Congratulations on the quarter. For my first question, could you discuss the persistency rates among patients in the Voyage and Panorama studies that you're observing in a blinded manner, and how those might be trending compared with the dropout rates you had presumed in the trial design? Also, regarding what we should expect on the communication side, should we take it that whenever you carry out the sample size re-estimation, that information won't be disclosed publicly? Then I have one or two additional questions.
Yes. Thank you very much for asking; we won't say anything about studies that are ongoing or even unblinded data from them until we reach a stage where we have data and can fully announce a study's outcomes. Yet we've definitely felt quite encouraged by a lot of the metrics, but — and truly every metric we've been tracking in the trials and remain dedicated to running these studies at the highest quality and on schedule and reaching results at the right time next year. And once more, we haven't said anything specific about whether we would publicly announce a sample re-estimation or not.
Understood. Next, regarding the Panorama and Ascend trials, which each include two doses of MM120, once the data come in — particularly from a regulatory standpoint — what magnitude of separation between those doses would you hope to observe, or what do you believe the FDA would want to observe, when it comes to efficacy and safety, in order to resolve the functional unblinding concern, or perhaps the question of a dose-dependent shift between the doses?
The key thing here, I believe, is that programs need to show dose response. So, when we consider issues such as functional unblinding — which affect all of psychiatry, and really anything in the CNS, naturally — we view demonstration of dose response as truly essential, and it provides a strong level of confidence that a drug's treatment effect is genuine. That is the reason we ran the Phase II study that we did, and, uniquely within our field, have thoroughly characterized the dose response. We have a study that is finished and has been published, and we are very excited about it, naturally, which showed both clinically, from an observational standpoint, and statistically, that a dose response exists. And that held true even though virtually every patient, no matter which dose of active drug they got, reported being functionally unblinded by correctly guessing they had received drug. So, at this stage, there is not really any doubt in our minds about whether a dose response exists, since we conducted a dedicated study to show it, and that study successfully established that it does. Consequently, the availability, the existence of the lower dose — the 50-microgram arm — truly serves as a kind of prospective element in the study, and it lets us, during the consent process, sort of confound expectations by effectively telling a patient that if they feel the effects of drug on the day of dosing, they cannot assume it is the full real dose of drug. It actually is the dose of drug from the earlier study that we demonstrated is functionally unblinding yet lacks clinical activity in reducing anxiety symptoms. So, it is a design element and a sort of functional control within the study. However, as far as the data outcomes go, the primary outcome measures in both Voyage and Panorama and in Emerge and Ascend test 100 micrograms against placebo, and no result from the 50-microgram group can change the finding of that primary analysis. Thus, no matter what occurs with respect to the group response to 50 micrograms, we will be seeking to clinically and statistically prove that MM120 100 micrograms is superior to placebo.
Understood. That's quite useful. Perhaps for my final question, if there's room for one more. Many KOLs have told us that a major point of differentiation, and possibly a significant unmet need, is the ability to lower how often retreatment happens. Could you speak to any follow-up or experience from the Phase II that might shed light on the sort of timeframe range in which patients would need to be retreated?
Yeah. So, based on what we observed with the average curves and response, no decline in effect appeared through 12 weeks. Given that, we truly cannot even try to extrapolate those curves and pinpoint a moment when we could confidently expect patients to require another treatment. And naturally, we're working to characterize that within Part B of our Phase III studies, which are underway and planned. We definitely hear about, and have examined, real-world use and the compassionate use programs, and the durability of LSD has been encouraging, sometimes lasting considerably past 12 weeks in certain of those studies, and we're genuinely excited to characterize that rigorously within our Phase III program. Still, it's somewhat premature to state with certainty or precision where retreatment should be expected, though what we do know is that — and we feel we have alignment on the proper method for characterizing this, which is to do precisely what we're doing in Part B of the Phase III studies, meaning screening patients and, upon symptom recurrence, using a 16 or greater or a MADRS of 20 greater depending on the study, the option of open-label retreatment, and attempting to characterize those dynamics, the gaps between doses and the eventual frequency across a 12-month period in the study. So, we're really excited to reach that data, but it's a bit premature to say so today.
Great to see how things are moving forward. I've got a handful of questions. To start, since MDD tends to be more episodic, while GAD is characterized more by chronic features, should we anticipate any variation in how long MM120's effects last? And what might that imply regarding how many treatments are needed each year for each condition? Also, would you anticipate that the price for each treatment with MM120 would be identical for GAD and MDD? And I have one more question after that.
Yeah. Thanks a lot, Sumant. I mean, that's precisely the reason these studies are being run—to try to pin that down; we think, given what we've observed and the curves I mentioned earlier for both anxiety and depression symptoms in the Phase II, the response patterns looked fairly comparable; so we are definitely highly focused and very keen on nailing down those treatment responses and retreatment characteristics, and that will absolutely shape everything from how we handle clinical, regulatory, and pricing conversations.
Understood. Then for my second question — looking at Slide 23, within the MM120 commercial framework in your most recent deck, it states that psychotherapy isn't provided or mandated, though it can be supplemented beyond a dosing session depending on each person's needs and goals. So when it comes to actual practice, what share of patients do you believe this could apply to? And what effect would that have on commercial or reimbursement-related factors?
Sure — on the whole, our hope is that all patients can access every available treatment; we recognize that psychotherapy today isn't especially well reimbursed, and with MM120, altering that isn't our stance or our role; therefore, in real-world settings, we definitely anticipate that a number of patients already receiving psychotherapy would be suitable for MM120 and would probably be able to stay on it. Again, through what we've observed in the broader world, we've seen patients both in academic trials and in everyday practice who receive a psychedelic and afterward choose to take up psychotherapy. So naturally, we want labeling and a development effort that supports the broadest uptake and the broadest range of use cases for MM120 once it's approved and available. Yet within the development program itself, we neither mandate nor provide any form of psychotherapy.
Two things I'd like to ask. First, my understanding is that you said the GAD Phase III trial has 90% power for spotting a 5-point HAM-A gain. Compared with the 7.7 point placebo-adjusted gap that showed up in Phase IIb, I'd add. Could you frame that 5-point bar in clinical terms for me? In terms of real-world outcomes for patients, how are we meant to gauge its importance? Then, regarding the depression study Emerge, a point of clarification, I suppose: have you disclosed the powering for that trial too, plus what you anticipate ahead of that mid-2026 data readout?
Yes. Patrick, many thanks for those questions. Yes, so looking at the setting of past and presently cleared treatments for generalized anxiety disorder, what we generally observe is a placebo-adjusted change below 5 points, and more often, roughly the mid-3 point over placebo. And in absolute terms, usually within the low-teens when it comes to the absolute size of HAM-A improvement for those approved therapies. So against that backdrop, at 12 weeks following one dose of drug, we saw close to a 22-point improvement, with the 7.7 placebo-adjusted delta, in our Phase II study. And so, naturally, we're aiming to be conservative with powering assumptions, so we give ourselves a solid probability of success. That same method carries over. In both GAD and in MDD, what we want to see is a clinically meaningful change, and that is the way we've handled the powering and design across all 4 of the Phase III studies.
So I believe you called 2025 a period of productive talks with the FDA. Could you go into detail about which main areas you've reached agreement on up to now, and what remains to be wrapped up before possible NDA filings? Also, would you plan to file the NDA for GAD using the 12-week data, or would you instead require longer-term data from Part B before you file?
Yes. Our dialogue with FDA has been continuous and extremely productive, and we are quite thankful for how engaged they've been through the breakthrough therapy designation program. We have genuinely made the most of that, attempting to maintain continual communication and a strong level of agreement regarding every study we are running, especially the Phase III trials. So we generally avoid discussing particular agency interactions while they're ongoing, yet we do feel there is a strong level of agreement. In our view, the key data is what we must generate from Part A of our Phase III trials to show, at 12 weeks in GAD and at 6 weeks in MDD, that we have 2 studies demonstrating, we hope, the safety and efficacy of MM120. That has been our strategy. And once more, extremely productive communication. As we move forward and produce pivotal data throughout 2026, we will keep that communication going and do it all. The team has a remarkable history of reaching our milestones and operating our program with tremendous efficiency. We keep doing that in clinical development. We plan to keep doing that across the remaining regulatory and commercial milestones that lie ahead.
One final thing — might there be an FDA advisory committee meeting included in the review for GAD, for MDD, or for both? And in what way does your clinical development program leave you ready for that conversation?
What we've aimed to do is build the most compelling and most robust body of evidence and data package, capable of withstanding scrutiny from any stakeholder, in any form. So regardless of whether an advisory committee ends up being needed, we will definitely be ready — though it's too early to state that until we reach that point in the review cycle and have held the dialogue with FDA at that time, to determine one way or the other if an advisory committee would be necessary.
Can you hear me now?
Yes, we can.
All right. Sounds good. Yeah, my apologies. I believe my connection is a bit unstable. Nice work on the quarter. About the Phase III trials that are ongoing right now, could you expand a little on how safety is being watched during that interim 3-month window after the first dose is given? I'm simply wondering what safeguards exist for patients, and how you balance giving these patients support without straying into psychotherapy? And after that, I have one more question.
Sure, I'll hand it to Dan.
Absolutely, and that's a really good question. Naturally, we're focused on keeping people safe while they're taking part in our trials. Across the whole time each person is enrolled — which spans the entire year — participants stay in ongoing communication with the site, and we conduct routine AE evaluations. We also administer C-SSRS assessments on a regular basis to confirm that nobody has become suicidal; we pay very close attention to these matters; however, that style of oversight aligns fully and logically with how psychiatric drug development has always been handled. It also reveals something about the field and the presumptions that existed before certain research we conducted regarding what was needed to study this category. So then, there's a distinction between safety monitoring and, should a participant experience a safety problem and we had to send them to a higher level of care, naturally, that would be possible. When that happens, the individual would be removed from the trial, since that would count as an event resulting in early discontinuation; yet none of that comes anywhere near trying to alter symptoms via engagement and interaction. Therefore, none of that — by no means does any portion of that safety monitoring come close to the kinds of interventions that would amount to psychotherapy.
Let me close with a single last remark to drive this home. The term psychotherapy is a constructed definition, and it carries a lengthy history behind it. In my view, various efforts have arisen that muddy what the term actually means. Because of that, we take great care in the guidance we give sites on running the trial — namely, that psychotherapy must explicitly not be provided while our studies are being carried out — and throughout our development program we have kept adherence to that instruction at a very high level.
Great, great. That's really useful. Now, very quickly, on the treatment session itself: do you already have procedures set up in case, in that uncommon situation, someone needs to remain past the 8-hour mark? And will instances of that be part of what shows up in the final data readout?
It's too early to specify precisely what data we would share and when. We do plan, once we have topline results from our Phase III trials, to make our disclosures complete. That said, we have arrangements and backup arrangements ready for every kind of scenario, as is true of any clinical trial. Still, the ODT formulation and the way we handle patient safety monitoring in Phase III have left us quite encouraged. Watching what we've seen to this point, across our whole development program, has been genuinely encouraging, and it fits with what we're trying to do: build an incremental body of evidence that leads to a truly efficient delivery framework, ideally for labeling discussions and for commercializing the product.
To our speakers, we've reached the end of the question-and-answer portion for today. That brings today's conference call to a close. We appreciate everyone for joining in. At this point, all of you are free to hang up. Enjoy the rest of your day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Mind Medicine (MindMed) Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Mind Medicine (MindMed) Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.